Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) PT at $15.00

Shares of Nkarta, Inc. (NASDAQ:NKTX) have been given a consensus recommendation of “Buy” by the seven analysts that are presently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $15.00.

NKTX has been the subject of a number of research analyst reports. RODMAN&RENSHAW raised shares of Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Rodman & Renshaw began coverage on Nkarta in a research note on Wednesday, October 9th. They issued a “buy” rating and a $14.00 price target on the stock. Mizuho reduced their price objective on Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research report on Thursday, November 21st. Needham & Company LLC dropped their target price on Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Finally, HC Wainwright reduced their price target on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, November 11th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Meeder Asset Management Inc. purchased a new position in Nkarta during the second quarter valued at approximately $26,000. Erste Asset Management GmbH bought a new stake in shares of Nkarta during the 3rd quarter valued at $33,000. GAMMA Investing LLC lifted its stake in shares of Nkarta by 110.9% during the 3rd quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock valued at $45,000 after buying an additional 5,243 shares in the last quarter. Forefront Analytics LLC purchased a new position in shares of Nkarta during the 2nd quarter valued at $70,000. Finally, Intech Investment Management LLC bought a new position in Nkarta in the 3rd quarter worth $74,000. 80.54% of the stock is currently owned by institutional investors.

Nkarta Stock Down 0.4 %

Shares of NASDAQ NKTX opened at $2.41 on Monday. The firm’s 50-day moving average price is $2.84 and its 200-day moving average price is $4.54. Nkarta has a 52-week low of $2.08 and a 52-week high of $16.24. The company has a market cap of $170.07 million, a PE ratio of -1.28 and a beta of 0.82.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.